RecruitingNot ApplicableNCT07512557

Probiotic Research On Safety, Palatability, Efficacy and Receptivity

Evaluating the Effectiveness and Feasibility of a Probiotic Intervention to Improve Nutrient Levels in Reproductive-Aged Women: A Pilot Study


Sponsor

Carleton University

Enrollment

82 participants

Start Date

Nov 28, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this pilot study is to determine if taking a commercially available probiotic product can influence levels of vitamins B12, B6 and folate after a 4-week supplementation period in reproductive-aged women without any micronutrient deficiencies. The main question it aims to answer is: • Does a probiotic product influence blood folate, vitamin B12 and B6 levels in reproductive-aged women when it is taken regularly for 4 weeks? Participants in this clinical trial will consume the probiotic product containing multiple probiotic strains regularly for 4 weeks. One group will consume one capsule per day at a particular dose, and the second group will consume two capsules per day at another dose. Participants will also have to: * Attend two in-person visits with a researcher: at enrolment (baseline), and endline (day 28/4 weeks) * Provide a blood sample at baseline (day 0) and endline (day 28/4 weeks) * Provide two stool samples (following each in-person visit) * Complete an online "study diary" every two weeks for 4 weeks (2 study diaries) * Complete two sets of online questionnaires (following each in-person visit) * Complete two sets of dietary assessments (following each in-person visit)


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 40 Years

Inclusion Criteria7

  • Non-pregnant and non-lactating
  • English speaking with the ability to give informed consent
  • -40 years of age (inclusive)
  • Women who are biologically female
  • Willing and able to agree to the requirements and lifestyle restrictions of this study
  • Able to understand and read the questionnaires in English and carry out all study-related procedures
  • Located in the greater Ottawa area and a resident of Ontario

Exclusion Criteria12

  • Individuals who are lactating, pregnant, or planning to become pregnant during the study
  • Individuals who are not maintaining adequate birth control measures
  • Adequate birth control measures include any option that will adequately prevent pregnancy including: contraceptives, lifestyle choices, complete abstinence, or as a result of other medical methods, procedures, or conditions
  • Have a known sensitivity, intolerability, or allergy to any of the study products or their excipients
  • Are using vitamin and mineral supplements containing B vitamins
  • Intake of a B-vitamin-containing micronutrient supplement or probiotic product in the previous 4 weeks
  • Expecting to change diet and exercise regimen in the next 4 weeks
  • Have planned surgery during the course of the study
  • Use of investigational product(s) in another research study within 30 days prior to the baseline visit or during the study duration
  • Taking probiotics during the study period
  • More than 2 alcoholic beverages per day throughout the duration of the study
  • Known medical history of specific conditions including: Gastrointestinal disorders: celiac disease, ulcerative colitis, and Crohn's disease; Gastric cancer and gastric polyps; Inflammatory bowel diseases; Helicobacter pylori infection; Gastrectomy, duodenal bypass, bariatric surgery

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTProbiotic Capsule

Jamieson 10 Billion Daily Maintenance Probiotic. The probiotic formulation contains Bifidobacterium animalis subsp. lactis (UABla-12), Lactobacillus paracasei (UALpc-04), Bifidobacterium breve (UABbr-11), Lactobacillus gasseri (UALg-05), Lactobacillus rhamnosus (UALr-06), Lactobacillus rhamnosus (UALr-18), Lactobacillus acidophilus (DDS-1), Lactobacillus plantarum (UALp-05), Bifidobacterium longum subsp. longum (UABl-14), Bifidobacterium bifidum (UABb-10), Lactobacillus casei (UALc-03), Lactobacillus reuteri (UALre-16), Lactococcus lactis (UALl-08), and Bifidobacterium longum subsp. infantis (UABi-13).


Locations(1)

Carleton University

Ottawa, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07512557


Related Trials